Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Cancer Res. 2012 Jan 20;72(6):1494–1503. doi: 10.1158/0008-5472.CAN-11-3948

Table 2. ARN-509 and MDV3100 steady-state levels in plasma- and brain-tissue.

ARN-509 and MDV3100 were measured in plasma- or brain-tissue following 28d daily-dosing at 10 mg/kg/day. Plasma and brain were isolated 24h after final-dose on d28. ARN-509 and MDV3100 levels quantified using an LC/MS method.

Dose (mg/kg/day) # mice a Plasma C24hr (μg/mL) a Brain C24hr (μg/g) Brain:Plasma (%)
ARN-509 10 8 1.64 ± 0.30 0.479 ± 0.132 29.3 ± 6.3
MDV3100 10 5 10.5 ± 2.3 2.01 ± 0.83 18.8 ± 4.4
a

mean